Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
488 Phase 1 trial of first-in-class anti-CD96 monoclonal antibody inhibitor, GSK6097608, monotherapy and combination with anti–PD-1 monoclonal antibody, dostarlimab, in advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.